Neutralizing Antibody Protection: Where Do We Go From Here?
Presentation: The Antibody Mediated Prevention (AMP) trials did not demonstrate HIV prevention efficacy (PE) of the CD4-binding-site-targetting broadly neutralizing antibody (bnAb), VRC01 (10mg/kg or 30mg/kg IV vs. placebo). However, 75% PE was observed against viruses sensitive to VRC01 with an IC80 200 at the estimated time of exposure to a given exposing virus was associated…